Immunovia AB (IMMNOV) Stock Statistics & Valuation Metrics

Immunovia AB has a market cap or net worth of kr114.22M. The enterprise value is -kr20.47M.

Immunovia AB has 672,666,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunovia AB’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -121.21%.

The current PE Ratio of Immunovia AB is ―. Immunovia AB’s PEG ratio is 0.00.

In the last 12 months, Immunovia AB had revenue of 685.00K and earned -145.91M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -78.40M and capital expenditures -5.56M, giving a free cash flow of -83.96M billion.

Immunovia AB pays an annual dividend of ―, resulting in a dividend yield of ―

Immunovia AB upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Immunovia AB as a current ratio of ―, with Debt / Equity ratio of -246.59%

In the past 12 months, Immunovia AB has paid 0.00 in taxes.

Immunovia AB EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.02.

Immunovia AB has kr77.46M in cash and marketable securities with kr857.00K in debt, giving a net cash position of kr76.60M billion.

Gross margin is -3789.68%, with operating margin of ―, and net profit margin of ―.

The average price target for Immunovia AB is ―, which is 11.43% higher than the current price. The consensus rating is ―